NanoViricides Highlights Broad-Spectrum Antiviral Candidate Amid Ebola Outbreak

NanoViricides, Inc. (NYSE American: NNVC), a clinical-stage antiviral drug developer, highlighted the potential of its broad-spectrum antiviral candidate NV-387 in response to the ongoing Bundibugyo Ebola outbreak in the Democratic Republic of Congo and Uganda. The company stated that the oral drug candidate could offer a differentiated approach if proven effective against the virus strain.

NV-387's proposed mechanism targets viral cell attachment pathways common across filoviruses, positioning the candidate as a potential pandemic preparedness tool for Ebola and related viral threats. The company emphasized that its technology could address the urgent need for effective treatments against emerging viral diseases.

According to the press release, NanoViricides' lead drug candidate NV-387 is a broad-spectrum antiviral drug being developed for the treatment of RSV, COVID, Long COVID, Influenza, and other respiratory viral infections, as well as MPOX/Smallpox infections and Measles. The company is currently focused on advancing NV-387 into Phase II human clinical trials.

The announcement comes as the Democratic Republic of Congo and Uganda grapple with an Ebola outbreak caused by the Bundibugyo strain. Current treatments for Ebola are limited and often require intravenous administration, making an effective oral drug like NV-387 a potentially valuable addition to the medical arsenal.

NanoViricides' platform technology is based on the TheraCour nanomedicine technology, which it licenses from TheraCour Pharma, Inc. The company holds a worldwide exclusive perpetual license for several drugs targeting specific mechanisms for the treatment of various human viral diseases, including HIV/AIDS, Hepatitis B and C, Rabies, Herpes Simplex Virus, Influenza, Dengue viruses, Ebola/Marburg viruses, and certain Coronaviruses.

The company noted that drug development is extremely lengthy and requires substantial capital, and there can be no assurance that any of its pharmaceutical candidates will show sufficient effectiveness and safety for human clinical development. The latest news and updates regarding NNVC are available in the company’s newsroom at https://ibn.fm/NNVC.

For more information on the full press release, visit https://ibn.fm/mm3Z5.

NanoViricides' business model is based on licensing technology from TheraCour Pharma Inc. for specific application verticals of specific viruses, as established at its foundation in 2005. The company's advanced drug candidate NV-HHV-1 for the treatment of Shingles is also in development.

The company believes that its nanoviricide technology represents a novel approach to antiviral therapy, creating special purpose nanomaterials that can potentially overcome limitations of traditional antiviral drugs.